NCT05064865

Brief Summary

Aging epidemics in Singapore are rapidly increasing and Age-related macular degeneration (AMD) prevalence is significantly associated with older age. This study aims to understand the effect of consuming freeze-dried table grape powder on AMD in an older population.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 30, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 1, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

January 28, 2022

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2022

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

November 9, 2023

Status Verified

November 1, 2023

Enrollment Period

7 months

First QC Date

August 30, 2021

Last Update Submit

November 7, 2023

Conditions

Keywords

Eye HealthAge-related Macular Degenerationcarotenoids

Outcome Measures

Primary Outcomes (3)

  • Change in macular pigment optical density

    Macular pigment optical density will be measured using macular pigment scanner

    Every four weeks (week 0, week 4, week 8, week 12, week 16)

  • Change in skin carotenoid status

    Skin carotenoid status (a.u) measured using NuSkin II, resonance Raman spectroscopy

    Every four weeks (week 0, week 4, week 8, week 12, week 16)

  • Change in blood carotenoid concentration

    Blood carotenoid concentration to be quantified by HPLC

    Every eight weeks (week 0, week 8, week 16)

Secondary Outcomes (15)

  • Change in flow mediate dilation

    week 0 and week 16

  • Change in endothelial function

    week 0 and week 16

  • Change in the concentration if Endothelin-1 in plasma

    week 0 and week 16

  • Change in the concentration if Nitric Oxide in plasma

    week 0 and week 16

  • Change in body weight

    Every four weeks (week 0, week 4, week 8, week 12, week 16)

  • +10 more secondary outcomes

Study Arms (2)

Freeze-dried table grape powder

EXPERIMENTAL

The intervention group will consume 46 g/day of a freeze-dried table grape powder.

Dietary Supplement: Freeze-dried table grape powder

Placebo grape powder

PLACEBO COMPARATOR

The control group will consume the same amount of a placebo with a similar taste to the table grape powder.

Dietary Supplement: Placebo of the table grape powder

Interventions

Consumption of 46g/day freeze-dried table grape powder

Freeze-dried table grape powder

Consumption of 46g/day placebo version of the freeze-dried table grape powder

Placebo grape powder

Eligibility Criteria

Age60 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female participants, aged between 60 and 85 years old inclusive
  • Able to give informed consent in English

You may not qualify if:

  • Smokers
  • Allergy to grapes
  • Known eye diseases (macular degeneration, cataracts, retinopathy or glaucoma), blindness in at least one eye or have had eye surgery
  • Abnormal kidney and liver function
  • Taking eye medication and/or dietary supplements for the eyes for the past 3 months
  • Taking supplements containing carotenoids (e.g. Vitamin A, lutein, zeaxanthin) for the past 3 months
  • Currently on type 2 diabetic medication.
  • Currently on anti-hypertensive or cholesterol-lowering; unless this prescription has been ongoing for more than 3 years prior to study participation.
  • Currently on a specialized diet (e.g. vegetarian, vegan, weight loss diet, low fat diet)
  • Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider or 45ml of distilled spirit.
  • Significant change in weight (≥ 3 kg body weight) in the past 3 months
  • Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
  • Poor peripheral venous access based on past experiences with blood draw
  • Participating in another clinical study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National University of Singapore

Singapore, 117546, Singapore

Location

Related Publications (2)

  • Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-71. doi: 10.1080/07853890600946724.

    PMID: 17101537BACKGROUND
  • Hu W, Zheng R, Feng Y, Tan D, Chan Chung-Tsing G, Su X, Kim JE. Impacts of regular consumption of grapes on macular pigment accumulation in Singapore older adults: a randomized controlled trial. Food Funct. 2023 Sep 19;14(18):8321-8330. doi: 10.1039/d3fo02105j.

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Study Officials

  • Jung Eun Kim

    National University of Singapore

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

August 30, 2021

First Posted

October 1, 2021

Study Start

January 28, 2022

Primary Completion

August 31, 2022

Study Completion

October 1, 2024

Last Updated

November 9, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Electronic copies of the data with identifiable participant information will be key data will be de-identified prior to statistical analysis

Locations